Literature DB >> 11446130

Dialysis for end-stage renal disease. Determining a cost-effective approach.

L Kirby1, L Vale.   

Abstract

OBJECTIVE: Renal replacement therapy (RRT) is essential for maintenance of life for those with end-stage renal disease. However, there remain many areas of uncertainty about which method of RRT should be chosen. This paper reports an economic model based on a systematic review that attempts to determine which method of dialysis, continuous ambulatory peritoneal dialysis (CAPD) or hemodialysis, a patient should have as the initial method of RRT.
METHODS: A systematic review and a costing exercise carried out in a Scottish hospital were used to populate a Markov model. Scenario analysis was used to model plausible variations in variables included in the model.
RESULTS: In 8 of the 16 scenarios developed hemodialysis dominated CAPD. In a further eight scenarios, the cost per life-year displayed considerable variability, ranging from between 5,000 Pounds to 51,000 Pounds. The higher costs per life-year were associated with minimum estimates of additional survival for a patient starting RRT on hospital hemodialysis.
CONCLUSION: It may be more cost-effective to manage patients starting on RRT with hospital hemodialysis than CAPD. This has particular implications for the United Kingdom, given that up to 50% of new patients receive CAPD.

Entities:  

Mesh:

Year:  2001        PMID: 11446130     DOI: 10.1017/s0266462300105045

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  7 in total

1.  Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA.

Authors:  Tadesse M Abegaz; Vakaramoko Diaby; Fatimah Sherbeny; Askal Ayalew Ali
Journal:  Clin Drug Investig       Date:  2022-05-25       Impact factor: 2.859

2.  A cost evaluation of peritoneal dialysis and hemodialysis in the treatment of end-stage renal disease in Sao Paulo, Brazil.

Authors:  Mirhelen Mendes de Abreu; David R Walker; Ricardo C Sesso; Marcos B Ferraz
Journal:  Perit Dial Int       Date:  2012-12-03       Impact factor: 1.756

3.  Estimating the financial cost of chronic kidney disease to the NHS in England.

Authors:  Marion Kerr; Benjamin Bray; James Medcalf; Donal J O'Donoghue; Beverley Matthews
Journal:  Nephrol Dial Transplant       Date:  2012-08-05       Impact factor: 5.992

4.  The financial impact of increasing home-based high dose haemodialysis and peritoneal dialysis.

Authors:  Frank Xiaoqing Liu; Catrin Treharne; Bruce Culleton; Lydia Crowe; Murat Arici
Journal:  BMC Nephrol       Date:  2014-10-02       Impact factor: 2.388

Review 5.  Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design.

Authors:  Daniel M Sugrue; Thomas Ward; Sukhvir Rai; Phil McEwan; Heleen G M van Haalen
Journal:  Pharmacoeconomics       Date:  2019-12       Impact factor: 4.981

6.  Peritoneal dialysis and in-centre haemodialysis: a cost-utility analysis from a UK payer perspective.

Authors:  Catrin Treharne; Frank Xiaoqing Liu; Murat Arici; Lydia Crowe; Usman Farooqui
Journal:  Appl Health Econ Health Policy       Date:  2014-08       Impact factor: 2.561

Review 7.  Clinical, patient-related, and economic outcomes of home-based high-dose hemodialysis versus conventional in-center hemodialysis.

Authors:  Nicos Mitsides; Sandip Mitra; Tom Cornelis
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-07-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.